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NOTES AND COMMENTS 
The Second International Symposium in Infection Models in 
Antimicrobial Chemotherapy 
In July 1996 (17-20), two years after the first edition 
held in Helsinore (Denmark), the second symposium 
on the role of animal models in the investigation of 
antimicrobial chemotherapy took place in Reykjavik, 
Iceland, under the auspices of the International Society 
for Antiinfective Pharmacology (ISAP) and European 
Network for the Study of Experimental Infections 
(ENSEI), a working group of the European Society 
of Clinical Microbiology and Infectious Diseases 
(ESCMID). This symposium was chaired by Professor 
Sigurdur Gudmundsun. 
Several aspects of animal models of infections were 
discussed through main lectures, poster presentations 
and technical demonstrations: development of new 
models, pathophysiologic investigations leading to 
potentially new therapeutic targets and evaluation of 
new drugs or new modalities of administration of 
antiinfectives, in order to improve efficacy, reduce 
toxicity or prevent emergence of resistance. Special 
attention was paid to the ethical questions raised by the 
use of animal models: why do we need them? How 
could we insure that their use is scientifically sound and 
that the conditions of care to the animals are definitely 
humane? 
The Editorial Board of CMI has selected s i x  notes 
coming from the reports of this symposium, as they 
were thought to illustrate some of the current uses of 
and main questions raised by the models and to be 
of potential general interest for the readership of the 
Journal. These notes will appear divided into two parts 
in two consecutive issues. 
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Mycobacteria are major pathogens for humans. The 
recent increasing interest in these bacteria is justified, 
since tuberculosis remains the main cause of death due 
to an infectious disease, leprosy is still an important 
public-health problem in many developing countries, 
and the atypical mycobacteria, often considered, in the 
recent past, as harmless, are more and more recognized 
as major opportunistic pathogens, especially among 
patients with AIDS. The natural or acquired resistance 
of these bacteria to many antimicrobial agents and their 
ability to escape from some immune defense mech- 
anisms demonstrate the need to develop experimental 
models. 
MYCOBACTERIUM AVIUM 
Atypical mycobacteria are emerging pathogens among 
immunosuppressed patients. The Mycobacterium aviurn 
complex, including the two species M.  avium and, to a 
lesser extent, M.  irztracellulare, is a common cause of 
disseminated infection in patients with AIDS. Several 
experimental models of M .  auium infection have been 
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reported. :Vf. aviirrn is a primarily intracellular bacterium 
which niultiplies within phagocytic cellc. M, avitun is 
resistant to most antituberculous agents but may be 
surceptible in vitro to antibiotics belonging to different 
families. Because of the intracellular replication of 
LIJ. aviirrii, the MIC determination is not sufficient to 
predict the in vivo efficacy of the drugs tested. 
Macrophage models 
Different cells used 
Cell models permit assessment of the activity of 
antimicrobial agents against M .  aviuni when it is 
multiplying within niacrophages. Macrophages from 
different sources have been used. Mouse peritoneal 
macrophages can be obtained by peritoneal lavage 
of sacrificed mice; the cells harvested are already 
macrophages [ I ] .  Mouse alveolar niacrophages can 
be obtained by bronchoalveolar lavage [l]. The mouse 
macrophage cell line J774 is a continuous cell line, 
easier to use than cells directly isolated from animals 
[2,3]. Mouse bone marrow-derived macrophages can 
be obtained after bone marrow extraction [4]. Human 
peripheral blood monocyte-derived niacrophages are 
obtained from the blood of healthy donors [S,C, l .  
H~itiiaii alveolar macrophages from HIV-infected 
patients have been used [7] .  
Comparison of the different macrophage models 
When the activity of antibiotics was tested in difikrent 
cell models, results were rather similar. Yajko compared 
the evaluation of antibiotic activity in mouse 5774 cells 
m d  in Jveolar macrophages from HIV-infected 
p<itients 171. 
Evaluation of the antibiotic activity 
The macrophage nionolayer is inoculated by deposition 
of a susperision of :L1. t n ~ i i i n 7  IS ] .  After ingestion, extra- 
cellular bacteria are removed by washing. At day 0 
of infection, the intracellular bacterial inoculuin is 
measured. Macrophages, loaded with &I. avitin?, are 
cultured in the presence of different concentrations of 
aiitibiotic?. The coiicetitration of LLf. Livitrm within 
niacrophages can be measured at different time points. 
This method is time-limited, since, after 1 week, niacro- 
phages detach from the bottom of the chambers. 
Correlation with in vivo results 
Good intracellular mtiniicrobial activity is a necewry 
condition to predict the good in vivo activity of an 
antibiotic, but not a sufficient one. In a study with 
ethambutol, rihnipicin or clofazimine, the positive 
predictive value of a response in humans based on a 
response in macrophages has been estimated to be 7496, 
‘and the negative predictive value to be 82% [8]. After 
thir first step ofscreening 111 a cell model, a second step 
of 4creening in an animal model IS required. 
Animal models 
The beige mouse model 
The main animal model used is the beige niouse model 
[9-111. Beige mice are mutants of C57BL/h mice with 
decreased natural killer cell activity that often develop 
spontaneous tumors. In beige mice, some selected 
strains of iW. nvirrrn may give a rapidly increasing level 
of infection and may cause the death of some animals. 
The bacterial concentration in the spleen reaches levels 
higher than 10’ CFU per organ, and sometimes higher 
than 10’” CFU in a few week$. This expensive model 
provides a kind of immunodeficiency different from 
that of AIDS in humans. 
Correlation with activity in humans 
In a recent study with ethanibutol, rifanipicin or 
clofazimine, a correlation was not observed between 
bacteriostatic activity in beige mouse liver or spleen and 
the degree of bacteriologic response in humans 1121. 
The use of clofazimine in this study did not give the 
best opportunity to see ‘1 good correlation, since 
clofazimine is very difficult to study, either in vitro or 
in vivo. Results obtained with clofiazimine in the 
experimental models arc‘ not very reli<ible, the carry- 
over phenonienon being very proniinent w ~ t h  th i s  
drug. The experiments often give fake bactericidal 
results 
Other models using immunodeficient mice 
Alternative models of mice with cellular inirriurio- 
deficiency, such as TxCDI- mice, Thxb mice, or nude 
mice, have been sugge<ted. 
TxCIII- iiiice ‘ire CS7BL/6 mice thymectomized 
Jt 1 weeks of age and treated intravenously with anti- 
CII4 antibodies [ 131. 
Thxb mice are adult thvniectoniizcd BALU/c mice 
or (BALB/c x C57BL/6) hybrids that are subjected to 
lethal whole body gamma irradiation and arc recon- 
stituted with syngeneic bone marrow cells [ 14) .  
Nude mice require J sterile environmeiit. 
These niodelu. difficult to realize. are riot easily 
used for routine investigations. 
Model of ‘murine AIDS‘ 
Another approach is the so-called ‘niodcl 06 murine 
AIDS (MAIDS)’ [15]. Mice are infected with a retro- 
virus, niurine leukemia virur (MuLV), in order to 
induce immunodeficiency. However, this model does 
not miiiiic hunian AIDS, since an  Activation of 
T-lymphocytes is observed, without the expected 
exacerbation of M.  t i i i i i u i i i  infection. Thus, this model 
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ofretroviral infection of mice does not seem to be a 
reliable model of immunodepression for the study of 
hf. avium infection and its treatments [16]. 
Models using immunocompetent mice 
An easy model uses normal wiltl-type C57BL/6 mice. 
The bacterial concentration in the spleen reaches levels 
higher than lo6 CFU per organ, without the spon- 
taneous clearance of bacteria that is observed in Swiss- 
Webster mice [17,18]. Because the death of animals is 
not an indispensable endpoint for the evaluation of 
drugs, those model can be used for the evaluation of 
antibiotics. A limit of this model is that the bacterial 
concentrations remain lower than the concentrations 
required for the selection of resistant mutants. In this 
niodel using normal C57BL/6 mice, treatment should 
be started several weeks after the bacterial challenge, 
when the infection is well established and more difficult 
to treat. These stringent conditions are more relevant 
than when treatment is started early after bacterial 
challenge. 
Models using other animal species 
Other animal species are not easily used for antibiotic 
evaluation. Hamsters can be inoculated by the intra- 
tracheal route but only 86% of untreated animals are 
infected. Rats are resistant to M .  avium infection, 
except if treated with cyclosporin [19]. 
Main results obtained with these models 
These models, mainly used fix the testing of new 
antibiotics, permitted the demonstration of the activity 
of new macrolides such as clarithrornycin or azithro- 
niycin, of new rifamycins such as rifabutin, and of 
ethambutol [20,21]. Amikacin demonstrates good 
activity in experimental models. Clofazimine is very 
difficult to evaluate because of the carryover phen- 
omenon that is always observed with this drug, and that 
gives false bactericidal results. These models are also 
used for the evaluation of imrnunomodulating com- 
pounds, such as G-GSF, GM-CSF, or interleukin-10 
[22,23]. 
OTHER ATYPICAL MYCOBACTERIA 
Because other atypical mycobacteria were rarely 
recognized as a cause of infection in humans, the 
experimental study of these bacteria is very limited. 
Some experiments, either within macrophages or in 
niice, have been done. The main species studied were 
M.  xenopi, M .  kansasii, and some other species not 
pathogenic for humans 124,251. A recent model has 
been developed with M.  genavense. 
MYCOBACTERIUM TUBERCULOSIS 
As M. tuberculosis is more virulent than atypical myco- 
bacteria, security measures for the protection of the 
laboratory workers must be reinforced. 
Models 
The macrophage models used for the study of atypical 
mycobacteria infections may be used for the study of 
M.  tubevculosis infection [26,27]. 
In vivo, M.  tuberculosis infection may be evaluated 
in different strains of mice, including immunocom- 
petent mice, such as Swiss mice, BALB/c mice, or CD1 
albino niice. 
Main recent results 
Animal models have demonstrated the good activity of 
three new rifamycins: rifabutin, rifapentine, and the 
benzoxazinorifamycin KRh4-1648 [28,29]. Rrfapentine, 
having the longest half-life, was effective even when 
administered twice weekly; thus, rifapentine could be 
useful for the prevention of tuberculosis or for the 
continuation phase of the treatment of tuberculosis 
~301. 
MYCOBACTERIUM LEPRAE 
Because of the inability to grow M.  leprae in vitro, in 
vivo evaluation is required. 
The model of mouse footpad infection 
The main model used is the model of mouse footpad 
infection. Among new antibiotics, fluoroquinolones 
such as ofloxacin, macrolides such as clarithromycin 
and minocycline exhibited good activity [31,32]. These 
results permitted the design of new therapeutic regi- 
mens for leprosy that are currently being assessed in 
humans through World Health Organization trials. 
Macrophage model 
An in vitro model uses mouse peritoneal macrophages 
in the presence of radiolabeled palmitic acid, the growth 
of M.  leprae being measured by the release of radioactive 
phenolic glycolipid I [33] .  
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